OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
M&A Transactions
M&A Transaction Chart
Viridian publishes weekly data on M&A transactions in the Cannabis/CBD/Psychedelic industries. This data includes information about the buyer and seller (public/private, state/country location), deal size, deal structure (cash, stock, earn-out), pricing, share information, and deal implied valuation.
Week ended 06/28/2024
Week ended 06/28/2024
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
M&A Transactions Commentary
Week ended 06/28/2024
- The Largest Closed M&A Deal of the Week:
- On June 24, 2024, PharmaCyte Biotech (PMCB: Nasdaq) closed the first tranche of a $42M two-part strategic investment in MYMD Pharmaceuticals (MYMD: NYSE) for $14.00M, paid in stock.
- MYMD has reported statistically significant Phase 2 results for its next-generation oral drug for sarcopenia, an age-related decline in physical function.
- As of March 31, 2024, MYMD only had approximately $226K of cash and determined that it needed to raise funds. The company believes the investment from PharmaCyte will fund its clinical studies for its principal sarcopenia drug for the next two years.
Week ended 06/28/2024
This is the MA basic
Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.
Viridian publishes weekly insights on the M&A landscape in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful M&A transactions for that week, and commentary on market conditions, M&A deal structures, target regions for acquirers, and industry sectors ripe for consolidation.